Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • PvP Biologics

    - PMLiVE

    BMS, Takeda and Astex join AI training consortium

    The initiative focuses on training AI models to aid in drug discovery and development

    - PMLiVE

    Global Healthy Living Foundation and Medscape Education Join Forces to Bridge the Gap Between Patients and Providers with Immunology Education

    UPPER NYACK, N.Y.--(BUSINESS WIRE)--The Global Healthy Living Foundation (GHLF) today announced a new partnership with Medscape Education to advance patient-centered innovation within the Immunology Learning Nexus (Nexus), Medscape’s flagship multi-year...

    Medscape Education

    - PMLiVE

    Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

    The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

    - PMLiVE

    Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP

    The enzyme replacement therapy is now the first treatment approved in the UK for this patient population

    - PMLiVE

    Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma

    The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication

    - PMLiVE

    Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma

    Around 800 people in the UK are diagnosed with late-stage disease every year

    - PMLiVE

    Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer

    Up to 160,000 people in the US are affected by polycythaemia vera

    - PMLiVE

    Takeda and EU Innovative Health Initiative launch Crohn’s disease prevention study

    Approximately three million people in Europe are affected by inflammatory bowel disease

    - PMLiVE

    Recognizing C diff Awareness Month in 2024

    Every year, the medical community recognizes the month of November as Clostridioides difficile (C. diff) Awareness month. C. diff is a public health threat that causes around 500,000 infections every...

    Medscape Education

    - PMLiVE

    Takeda’s mezagitamab shows promise in immune thrombocytopenia

    The rare immunoglobulin-mediated autoimmune disease affects four in every 100,000 people annually

    - PMLiVE

    Takeda’s Fruzaqla approved by EC to treat metastatic colorectal cancer in adults

    Approximately 538,000 new cases of colorectal cancer were diagnosed in Europe in 2022

    - PMLiVE

    Takeda shares long-term results for HyQvia in rare neurological disorder CIDP

    The therapy is the first and only facilitated subcutaneous immunoglobulin treatment for CIDP

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links